Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 14;11(12):1826.
doi: 10.3390/biology11121826.

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany

Affiliations

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany

Hans-Peter Rihs et al. Biology (Basel). .

Abstract

Malignant mesothelioma (MM) is a severe disease mostly caused by asbestos exposure. Today, one of the best available biomarkers is the soluble mesothelin-related protein (SMRP), also known as mesothelin. Recent studies have shown that mesothelin levels are influenced by individual genetic variability. This study aimed to investigate the influence of three mesothelin (MSLN) gene variants (SNPs) in the 5′-untranslated promoter region (5′-UTR), MSLN rs2235503 C > A, rs3764246 A > G, rs3764247 A > C, and one (rs1057147 G > A) in the 3′-untranslated region (3′-UTR) of the MSLN gene on plasma concentrations of mesothelin in 410 asbestos-exposed males without cancer and 43 males with prediagnostic MM (i.e., with MM diagnosed later on) from the prospective MoMar study, as well as 59 males with manifest MM from Germany. The mesothelin concentration differed significantly between the different groups (p < 0.0001), but not between the prediagnostic and manifest MM groups (p = 0.502). Five to eight mutations of the four SNP variants studied were associated with increased mesothelin concentrations (p = 0.001). The highest mesothelin concentrations were observed for homozygous variants of the three promotor SNPs in the 5′-UTR (p < 0.001), and the highest odds ratio for an elevated mesothelin concentration was observed for MSLN rs2235503 C > A. The four studied SNPs had a clear influence on the mesothelin concentration in plasma. Hence, the analysis of these SNPs may help to elucidate the diagnostic background of patients displaying increased mesothelin levels and might help to reduce false-positive results when using mesothelin for MM screening in high-risk groups.

Keywords: MoMar cohort; asbestos; biomarker; blood test; confounder; manifest mesothelioma; mesothelin; prediagnostic mesothelioma; prospective study; variant.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Distribution of the number of single-nucleotide polymorphism mutations by study group. p values of Mann–Whitney U tests displayed mutation differences between groups with low (<2.9 nM, white boxes) and high (≥2.9 nM, dark grey boxes) concentrations of mesothelin. Light grey boxes depict the number of single-nucleotide polymorphism mutations in each study group without distinguishing mesothelin concentrations.
Figure 2
Figure 2
Association between haplotypes and mesothelin concentrations in 512 males stratified by study group. Samples without mutation (haplotype AAC) are marked in green, samples with one or two mutations are marked in white, and samples with three mutations (haplotype CGA) are marked in orange.

References

    1. Robinson B.W., Musk A.W., Lake R.A. Malignant Mesothelioma. Lancet. 2005;366:397–408. doi: 10.1016/S0140-6736(05)67025-0. - DOI - PubMed
    1. Robinson B.W., Lake R.A. Advances in malignant mesothelioma. N. Engl. J. Med. 2005;353:1591–1603. doi: 10.1056/NEJMra050152. - DOI - PubMed
    1. Pass H.I., Alimi M., Carbone M., Yang H., Goparaju C.M. Mesothelioma Biomarkers: A review highlighting contributions from the early detection research network. Cancer Epidemiol. Biomark. Prev. 2020;29:2524–2540. doi: 10.1158/1055-9965.EPI-20-0083. - DOI - PubMed
    1. Hassan R., Remaley A.T., Sampson M.L., Zhang J., Cox D.D., Pingpank J., Alexander R., Willingham M., Pastan I., Onda M. Detection and quantification of serum mesothelin, a tumour marker for patients with mesothelioma and ovarian cancer. Clin. Cancer Res. 2006;12:447–453. doi: 10.1158/1078-0432.CCR-05-1477. - DOI - PubMed
    1. Park E.K., Sandrini A., Yates D.H., Creany J., Robinson B.W., Thomas P.S., Johnson A.R. Soluble mesothelin-related protein in an asbestos-exposed population: The dust diseases board cohort study. Am. J. Respir. Crit. Care Med. 2008;178:832–837. doi: 10.1164/rccm.200802-258OC. - DOI - PubMed

LinkOut - more resources